At AAIC 2025, the chief executive officer at ALZpath discussed the growing adoption of the company’s pTau217 antibody blood test for AD research, emphasizing its potential role in early detection. [WATCH TIME: 4 minutes]
Mike Banville, MBA
Advertisement
Chief executive officer and president at ALZpath.
Articles by Mike Banville, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
How Multiple Sclerosis Affects Men
2
ECTRIMS Congress 2025: Top Expert Interviews and Key Takeaways
3
NeurologyLive® Brain Games: October 12, 2025
4
The Future of Disease-Modifying Therapy in Epilepsy
5
